218 related articles for article (PubMed ID: 35675517)
1. Single-cell spatial analysis of tumor immune architecture in diffuse large B-cell lymphoma.
Colombo AR; Hav M; Singh M; Xu A; Gamboa A; Lemos T; Gerdtsson E; Chen D; Houldsworth J; Shaknovich R; Aoki T; Chong L; Takata K; Chavez EA; Steidl C; Hicks J; Kuhn P; Siddiqi I; Merchant A
Blood Adv; 2022 Aug; 6(16):4675-4690. PubMed ID: 35675517
[TBL] [Abstract][Full Text] [Related]
2. Multiplex immunofluorescence staining and image analysis assay for diffuse large B cell lymphoma.
Lee CW; Ren YJ; Marella M; Wang M; Hartke J; Couto SS
J Immunol Methods; 2020 Mar; 478():112714. PubMed ID: 31783023
[TBL] [Abstract][Full Text] [Related]
3. High levels of Tim-3
Zhong W; Liu X; Zhu Z; Li Q; Li K
Int Immunopharmacol; 2021 Jul; 96():107662. PubMed ID: 33864956
[TBL] [Abstract][Full Text] [Related]
4. CCL8 as a promising prognostic factor in diffuse large B-cell lymphoma
Lou X; Zhao K; Xu J; Shuai L; Niu H; Cao Z; Wang J; Zhang Y
Front Immunol; 2022; 13():950213. PubMed ID: 36072582
[TBL] [Abstract][Full Text] [Related]
5. Prognostic implications of the tumor immune microenvironment and immune checkpoint pathway in primary central nervous system diffuse large B-cell lymphoma in the North Indian population.
Parkhi M; Chatterjee D; Bal A; Vias P; Yadav BS; Prakash G; Gupta SK; Radotra BD
APMIS; 2022 Feb; 130(2):82-94. PubMed ID: 34862664
[TBL] [Abstract][Full Text] [Related]
6. The tumour microenvironment is immuno-tolerogenic and a principal determinant of patient outcome in EBV-positive diffuse large B-cell lymphoma.
Keane C; Tobin J; Gunawardana J; Francis S; Gifford G; Gabrielli S; Gill A; Stevenson W; Talaulikar D; Gould C; Jain S; Birch S; Hertzberg M; Gandhi MK
Eur J Haematol; 2019 Sep; 103(3):200-207. PubMed ID: 31211907
[TBL] [Abstract][Full Text] [Related]
7. The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma.
Steen CB; Luca BA; Esfahani MS; Azizi A; Sworder BJ; Nabet BY; Kurtz DM; Liu CL; Khameneh F; Advani RH; Natkunam Y; Myklebust JH; Diehn M; Gentles AJ; Newman AM; Alizadeh AA
Cancer Cell; 2021 Oct; 39(10):1422-1437.e10. PubMed ID: 34597589
[TBL] [Abstract][Full Text] [Related]
8. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
[TBL] [Abstract][Full Text] [Related]
9. Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.
Xu-Monette ZY; Xiao M; Au Q; Padmanabhan R; Xu B; Hoe N; Rodríguez-Perales S; Torres-Ruiz R; Manyam GC; Visco C; Miao Y; Tan X; Zhang H; Tzankov A; Wang J; Dybkær K; Tam W; You H; Bhagat G; Hsi ED; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; van Krieken JH; Winter JN; Westin JR; Pham LV; Medeiros LJ; Rassidakis GZ; Li Y; Freeman GJ; Young KH
Cancer Immunol Res; 2019 Apr; 7(4):644-657. PubMed ID: 30745366
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of PD-1 and TIM-3 on CD3+ T cells from diffuse large B-cell lymphoma.
Zhang L; Du H; Xiao TW; Liu JZ; Liu GZ; Wang JX; Li GY; Wang LX
Biomed Pharmacother; 2015 Oct; 75():83-7. PubMed ID: 26463635
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma.
Xie M; Huang X; Ye X; Qian W
Int Immunopharmacol; 2019 Dec; 77():105999. PubMed ID: 31704289
[TBL] [Abstract][Full Text] [Related]
12. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
[TBL] [Abstract][Full Text] [Related]
13. Tumor Immune Microenvironment Components and Checkpoint Molecules in Anaplastic Variant of Diffuse Large B-Cell Lymphoma.
Xu T; Chai J; Wang K; Jia Q; Liu Y; Wang Y; Xu J; Yu K; Zhao D; Ma J; Fan L; Yan Q; Guo S; Chen G; Chen Q; Xiao H; Liu F; Qi C; Liang R; Li M; Wang Z
Front Oncol; 2021; 11():638154. PubMed ID: 34221962
[TBL] [Abstract][Full Text] [Related]
14. Intra-tumour heterogeneity of diffuse large B-cell lymphoma involves the induction of diversified stroma-tumour interfaces.
Sangaletti S; Iannelli F; Zanardi F; Cancila V; Portararo P; Botti L; Vacca D; Chiodoni C; Di Napoli A; Valenti C; Rizzello C; Vegliante MC; Pisati F; Gulino A; Ponzoni M; Colombo MP; Tripodo C
EBioMedicine; 2020 Nov; 61():103055. PubMed ID: 33096480
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological analysis of primary intestinal diffuse large B-cell lymphoma: Prognostic evaluation of CD5, PD-L1, and Epstein-Barr virus on tumor cells.
Ishikawa E; Kato S; Shimada K; Tanaka T; Suzuki Y; Satou A; Kohno K; Sakakibara A; Yamamura T; Nakamura M; Miyahara R; Goto H; Nakamura S; Hirooka Y
Cancer Med; 2018 Dec; 7(12):6051-6063. PubMed ID: 30449068
[TBL] [Abstract][Full Text] [Related]
16. The prognostic significance of immune checkpoint receptor expression in patients with lymphoma: Association with disease status and clinical outcomes.
Shokrgozar N; Dehghani M; Golmoghaddam H; Moghadam M; Rezaei N; Moayed V; Arandi N
Asia Pac J Clin Oncol; 2022 Oct; 18(5):e388-e397. PubMed ID: 35098660
[TBL] [Abstract][Full Text] [Related]
17. Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3
Zhang T; Ren T; Song Z; Zhao J; Jiao L; Zhang Z; He J; Liu X; Qiu L; Li L; Zhou S; Meng B; Zhai Q; Ren X; Qian Z; Wang X; Zhang H
J Immunol Res; 2020; 2020():6968595. PubMed ID: 33178839
[TBL] [Abstract][Full Text] [Related]
18. Tumour Microenvironment: The General Principles of Pathogenesis and Implications in Diffuse Large B Cell Lymphoma.
Sinkarevs S; Strumfs B; Volkova S; Strumfa I
Cells; 2024 Jun; 13(12):. PubMed ID: 38920685
[TBL] [Abstract][Full Text] [Related]
19. CD24 is a surrogate for 'immune-cold' phenotype in aggressive large B-cell lymphoma.
Higashi M; Momose S; Takayanagi N; Tanaka Y; Anan T; Yamashita T; Kikuchi J; Tokuhira M; Kizaki M; Tamaru JI
J Pathol Clin Res; 2022 Jul; 8(4):340-354. PubMed ID: 35289116
[TBL] [Abstract][Full Text] [Related]
20. Single-Cell Transcriptome Analysis Reveals Disease-Defining T-cell Subsets in the Tumor Microenvironment of Classic Hodgkin Lymphoma.
Aoki T; Chong LC; Takata K; Milne K; Hav M; Colombo A; Chavez EA; Nissen M; Wang X; Miyata-Takata T; Lam V; Viganò E; Woolcock BW; Telenius A; Li MY; Healy S; Ghesquiere C; Kos D; Goodyear T; Veldman J; Zhang AW; Kim J; Saberi S; Ding J; Farinha P; Weng AP; Savage KJ; Scott DW; Krystal G; Nelson BH; Mottok A; Merchant A; Shah SP; Steidl C
Cancer Discov; 2020 Mar; 10(3):406-421. PubMed ID: 31857391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
